Clinical trial
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant…
NCT00080054 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00080054 |
|---|---|
| Title | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas |
| Official title | Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Temozolomide for Treatment of Malignant Gliomas |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Neoplasm |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium Injection |
| Enrollment | 24 |
| First posted | Mar 23, 2004 |
| Last update posted | Apr 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: